Naltrexone Treatment Centers in Montana

No. Montana MAT providers do not require criminal-history disclosure to enroll. Federal law (42 CFR Part 2) protects substance-use treatment records; a criminal record will not block admission to a naltrexone program.

Cash-pay monthly cost for Sublocade in Montana typically runs $1,400–$1,900 per injection, plus administration fees. Manufacturer savings programs, 340B pricing at FQHCs, and State Opioid Response grants can significantly reduce this out-of-pocket cost.

Most Montana Medicaid (HELP Plan) plans have eliminated prior authorization for MAT medications, but long-acting injectables like Sublocade and Vivitrol may still require PA. Your Montana provider’s billing staff will handle any authorizations needed before your first dose.

Yes — federal parity rules require employer plans to cover MAT. High-deductible plans charge patient-paid rates until the deductible is met; HSA funds can be used for MAT and medication costs. Many employers also offer EAP programs that pay for an initial assessment.

Yes. Faces & Voices of Recovery chapters, the American Society of Addiction Medicine (ASAM) regional sections, and Montana-based recovery community organizations advocate for patient rights. SAMHSA’s Recovery Community Services Program funds peer-led groups in most Montana counties.

Many Montana patients stay on naltrexone for a year or more, and some stay indefinitely. Duration depends on individual stability, quality of life, and risk of relapse. Research consistently shows that longer MAT duration is associated with lower overdose mortality.

Same-day induction is increasingly common in Montana — especially for buprenorphine at low-barrier clinics and in emergency departments. Methadone same-day starts depend on OTP capacity; call early in the day to maximize your chance of same-day intake.

A positive urine drug screen is expected for most patients entering MAT — it confirms the diagnosis. Positive screens are not used to deny admission at any Montana SAMHSA-certified OTP. Your clinician interprets results and builds an individualized plan from there.

Methadone carries overdose risk during induction when the dose is being titrated, particularly in combination with benzodiazepines, alcohol, or other sedatives. Buprenorphine has a ceiling effect that lowers overdose risk. Naltrexone does not cause opioid overdose. Your Montana clinic monitors risk closely.

Yes. Postpartum continuation of MAT is strongly recommended — overdose risk is elevated in the postpartum period. Montana programs increasingly embed MAT within postpartum home-visiting programs to support the mother-infant dyad during the first year.

Peer-recovery support workers are trained individuals with lived recovery experience who provide mentoring, accompaniment to appointments, and navigation of resources. Montana Medicaid reimburses peer-support services; most mid-sized naltrexone providers employ certified peer specialists.

Only if disclosed under very narrow conditions — typically with your consent or specific court order. Being on prescribed naltrexone is legally protected and should not be used against you as a parent. Keep documentation of stability; consult a family-law attorney.